Dec 15, 2020
Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA
Dec 08, 2020
Cyxone receives regulatory approval to initiate a clinical Phase 2 study with Rabeximod in Covid-19 patients
Nov 10, 2020
Cyxone files patent application to extend exclusivity of Rabeximod
Sep 24, 2020
Cyxone revises the development plan for Rabeximod
Jul 08, 2020
Cyxone Signs Agreement With Professor Rikard Holmdahl as Senior Scientific Advisor
Jun 10, 2020
Cyxone Files New Patent Applications Following Additional Innovation Achievements
May 20, 2020
Dr Tara Heitner Appointed New CEO for Cyxone
Jan 29, 2020
Cyxone Orders More Rabeximod Substance and Confirms Timeline for the Phase IIb Program
Nov 21, 2019
Cyxone Signs a UK Contract Research Organization for Six-month Toxicology Studies With Rabeximod
Nov 13, 2019
Kjell G. Stenberg Steps Down as CEO of Cyxone
Sep 04, 2019
Cyxone Explores Orphan Drug Designation for Rabeximod
Aug 29, 2019
Cyxone's CEO Kjell G. Stenberg Acquires Additional Shares in the Company
Aug 02, 2019
Cyxone's T20K Shows Favorable Safety and Tolerability in First-in-human Trial
Jul 19, 2019
Cyxone Makes Further Strides With Rabeximod Phase IIb Trial by Signing CRO EGeen Inc.
Jul 12, 2019
Cyxone Announce Dosing of First Volunteer in T20K's First-in-human Trial
Jul 05, 2019
Cyxone Submits First Application to Start Clinical Phase IIb Trial With Rabeximod
Jul 01, 2019
First Berlin Equity Research Publishes Updated Independent Analysis of Cyxone
Jun 20, 2019
Cyxone Initiates First-in-human Trial With T20K for the Treatment of MS
Mar 20, 2019
Cyxone Announces Strategic Intent to Position its Drug Candidate T20K in MS as a Prophylactic Agent
Feb 04, 2019
Cyxone Announces Issuance of U.S. Divisional Patent for Drug Candidate T20K in MS